- Cardiovascular disease remains the leading cause of death in the United States.
- One of the most persistent challenges in cardiac care is patient delay in seeking care.
- HeartBeam is working to address this gap by transforming how ECG data are collected and used through its HeartBeam System.
Cardiovascular disease continues to be a major global health challenge, driven by aging populations, lifestyle factors and persistent gaps in early detection that continue to challenge healthcare systems. In response to these trends, HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising clinical need and evolving innovation.
The scale and severity of cardiac disease underscore the urgency of new approaches. According to the Centers for Disease Control and Prevention, cardiovascular disease remains the leading cause of death in the United States, accounting for more than 919,000 deaths in 2023, or roughly one in every three deaths, with someone dying from the condition every 34 seconds. More recent provisional data confirms that heart disease continued to rank as the leading cause of death in 2024, reinforcing its persistent impact. On a global scale, the World Health Organization estimates that cardiovascular diseases are responsible for approximately 17.9 million deaths each year, representing about 32% of all deaths worldwide.
Several converging factors are contributing to the continued rise of cardiovascular disease. Aging remains one of the most significant drivers, as risk increases substantially over time. At the same time, modern lifestyles marked by reduced physical activity, poor nutrition and chronic stress have accelerated the prevalence of key risk factors such as hypertension, obesity and diabetes. The American Heart Association has reported that these underlying conditions continue to rise, placing additional strain on healthcare systems and increasing the likelihood of cardiac events. Importantly, many cardiovascular events occur in individuals who were not previously identified as high risk, highlighting ongoing gaps in screening and monitoring.
One of the most persistent challenges in cardiac care is pre-hospital delay, with many patients not seeking medical attention at the onset of symptoms. Traditional electrocardiogram testing is typically conducted in clinical environments, which may not coincide with the onset of symptoms such as intermittent chest pain, palpitations or other warning signs. As a result, patients often defer care and clinicians are left without the data needed to make timely, informed decisions. This gap has fueled growing interest in portable, patient-driven monitoring technologies that can capture clinically relevant data outside traditional healthcare settings.
HeartBeam is working to address this gap by transforming how ECG data are collected and used. The company’s HeartBeam System is designed as a cable-free, high-fidelity ECG platform capable of capturing the heart’s electrical signals from three distinct directions for arrhythmia assessment. By collecting multidirectional signals, the system is intended to provide a more comprehensive representation of cardiac activity compared with conventional single-lead devices, which offer a more limited view.
The HeartBeam System uses a compact, credit-card size, portable design with embedded electrodes that allow patients to record ECG signals without adhesive patches or wires. This simplifies the user experience while maintaining the quality of data needed for clinical interpretation. The system’s ability to generate synthesized 12-lead ECG signals from these recordings is particularly significant, as it brings a level clinical-grade data traditionally associated with hospital-based equipment into a portable format. The HeartBeam System is currently FDA cleared for arrhythmia assessment and the company plans to submit for an indication expansion for heart attack detection in the future.
The importance of these capabilities becomes more apparent when considering the potential impact of earlier detection. Clinical research has consistently shown that faster identification of cardiac abnormalities can improve outcomes by enabling earlier intervention. In conditions such as arrhythmias or acute coronary syndromes, delays can lead to more severe complications, while timely detection can help guide treatment decisions and improve patient prognosis.
Beyond individual outcomes, improved tools may also help address broader system-level challenges. Healthcare systems are increasingly focused on reducing unnecessary hospital visits, improving triage efficiency and enabling more proactive management of chronic conditions. Technologies that allow patients to capture accurate cardiac data remotely can support these goals by providing clinicians with actionable information before a condition escalates.
HeartBeam’s approach reflects a broader shift in healthcare toward decentralized, patient-centered care. As digital health technologies continue to evolve, there is growing emphasis on empowering patients with tools that enable them to participate more actively in their own care. By combining portability with high-fidelity data capture, HeartBeam is positioning its technology within this emerging model, where clinical-grade ECGs are no longer confined to clinical settings.
The continued rise of cardiovascular disease highlights both the scale of the challenge and the need for innovation in how it is addressed. By focusing on earlier detection, improved accessibility and clinically meaningful data, HeartBeam is working to align its technology with the changing demands of modern healthcare. As the company advances its platform and expands its applications, its efforts underscore the critical role that innovation may play in addressing one of the most significant health challenges worldwide.
For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
